IMFINZI AstraZeneca Pty Ltd
Product name
IMFINZI
Sponsor
Accepted date
Jan-2024
Active ingredients
durvalumab
Proposed indication
Is indicated for the first-line treatment of adult patients with advanced or recurrent endometrial cancer.
Application type
C (new indication)
Publication date
Jan-2024